NCT00958906

Pilot Study for the Evaluation of Intravitreal Infliximab in the Treatment of Uveitic Macular Edema

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Icahn School of Medicine at Mount Sinai · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if intravitreal infliximab is a safe and effective treatment for macular edema secondary to uveitis.

Detailed description

Participants with uveitic macular edema will be treated with one injection of intravitreal infliximab (2.0mg/0.05ml) and followed for three months. Outcomes that be assessed include best-corrected visual acuity, macular thickness as measured by optical coherence tomography, and electroretinogram responses.

Conditions

• Uveitic Macular Edema
• Intraocular Inflammation

Interventions

Type	Name	Description
DRUG	Infliximab (intravitreal, 2.0mg/0.05ml)	One injection of intravitreal infliximab (2.0mg/0.05ml).

Timeline

• Start date: 2009-08-01
• Completion: 2009-10-01
• First posted: 2009-08-13
• Last updated: 2011-06-23

Locations

1 site across 1 country: United States